Tagworks Pharmaceuticals BV (“Tagworks”), a clinical-stage precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors, today announced the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for a Phase 1 clinical trial evaluating TGW101, a first-in-class antibody drug-conjugate (ADC) targeting tumor associated …
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing. Read More
NEXT Oncology Opens Newest Phase 1 Clinical Trial Center in Houston, Texas
With continued global expansion plans, NEXT Oncology is one of the largest Phase 1 Cancer Trial organizations in the world. (SAN ANTONIO, TX) March 25, 2025 ––NEXT Oncology has opened its seventh cancer care center in Houston, Texas as part of the company’s global growth initiative. NEXT – Houston, which will be led by Dr. Peter DeMaria and Dr. Jennifer …
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Read More
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the Phase 1 clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Read More
Phase 1 Studies of Novel Autologous CAR T-Cell Therapies Show Promise in GI Cancers
Two phase 1 studies report encouraging findings with use of novel autologous CAR T-cell therapies in gastrointestinal (GI) malignancies. Read More
NEXT Oncology Moves Cancer Research Forward
NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, played a significant role in moving cancer research forward at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago. Clinical investigators from NEXT locations around the world presented 25 abstracts, posters and presentations on the status of ongoing Phase 1 clinical trials at NEXT …
Novel IO Approaches Demonstrate High pCR Rates in the Neoadjuvant Setting, Questioning the Need for Surgery in Certain Patients With CRC
Despite recent advances in immunotherapy, certain subtypes of colorectal cancer, such as those that are MSI-high, dMMR of TMB-H, remain a treatment challenge. Moreover, the optimal therapeutic approach for colorectal cancer in the neoadjuvant setting remains elusive, with recent data pointing to combination approaches as potentially beneficial. Read More
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
NEW HAVEN, Conn., May 29, 2024 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug …
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced first clinical data from its Phase 1 dose escalation cohort of CLN-619 in combination with checkpoint inhibitor (CPI) pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors. Read More